Resmed Inc (RMD) Stock Analysis and Metrics

Resmed

NYSE: RMD

$195.30 ▲ +3.41 (+1.78%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap28.46 Bn

P/E18.73

P/S5.14

Div. Yield0.01

ROIC (Qtr)0.02

Total Debt (Qtr)664.10 Mn

Revenue Growth (1y) (Qtr)10.81

Add ratio to table…

About

ResMed Inc is a global leader in digital health and cloud-connected medical devices that designs innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. The company focuses on sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases, providing comprehensive residential care software platforms that support professionals and caregivers helping people stay healthy in the home or care setting of their choice.

ResMed Inc generates revenue through the sale of devices such as CPAP, APAP, bilevel, adaptive servo-ventilation, and high flow therapy systems, along with mask systems, diagnostic products, headgear, accessories, and dental devices. The company also earns revenue from cloud-based health applications, software, and devices that enable connected care, including patient engagement applications like myAir and remote monitoring platforms like AirView. Residential Care Software solutions contribute additional revenue by providing business management, electronic health records, revenue cycle management, and workforce management tools to healthcare providers in residential care settings.

ResMed Inc operates through the following segments: Sleep and Breathing Health segment and Residential Care Software segment.

• The Sleep and Breathing Health segment develops and commercializes continuous positive airway pressure treatment for obstructive sleep apnea, along with innovative products for respiratory disorders including ventilation devices, diagnostic products, mask systems for hospital and home use, headgear and accessories, and dental devices. This segment also provides cloud-based health applications and software designed to provide connected care, enabling clinicians to manage patients efficiently and encouraging long-term patient adherence to therapy.

• The Residential Care Software segment provides cloud-based solutions to healthcare providers operating in the residential care market, including home medical equipment and home infusion providers, home health and hospice agencies, skilled nursing facilities, private duty nursing organizations, senior living facilities, and life plan communities. These solutions support analytics, documentation management, reimbursement compliance, and data transfer as patients move between care settings, with capabilities for billing, business management, electronic medical records, revenue cycle management, operational analytics, patient engagement, and workforce management.

ResMed Inc holds a leading position in the sleep and breathing health market, competing with companies such as Philips BV, Fisher & Paykel Healthcare Corporation Limited, DeVilbiss Healthcare, Apex Medical Corporation, BMC Medical Co Ltd, React Health Corporation, Jiangsu Yuyue Medical Equipment & Supply Co Ltd, and Lowenstein Medical SE & Co KG. The company's competitive advantages stem from its focus on smaller, quieter, more comfortable, and more connected products, integration of artificial intelligence and machine learning algorithms to enhance therapy performance, and its extensive installed base of over 30 million patients using cloud-connected devices on AirView and over 10 million patients registered to the myAir platform.

ResMed Inc serves a diverse customer base including home medical equipment providers, health systems, sleep clinics, hospitals, durable medical equipment suppliers, home health and hospice agencies, skilled nursing facilities, senior living organizations, life plan communities, and individual patients diagnosed with sleep apnea, COPD, and other respiratory conditions. The company also works with prescribing practitioners, insurers, and durable medical equipment providers who assist patients in selecting and using its products.

Investment Thesis

▲ Bull case

ResMed's core mask portfolio, particularly the AirTouch N30i fabric-based technology, demonstrates a compelling competitive advantage with 6% higher 90-day adherence compared to silicone equivalents, which directly translates to increased patient lifetime value and resupply rates; this innovation is gaining strong early adoption in the higher-margin full-face category with the F30i Comfort and F30i Clear, and management noted these masks are "changing the basis of competition," creating a structural moat that is underappreciated by the market as a key driver of sustainable margin expansion beyond transient cost improvements.
The strategic acquisition of Noctrix Health for $340 million presents a significant hidden catalyst, as it brings a FDA de novo classified noninvasive nerve stimulation device (NIDRA) for restless leg syndrome (RLS), a condition affecting approximately 7% of the global adult population and 17 million in the U.S., with higher growth rates and gross margins than ResMed's existing business; management emphasized Noctrix's reimbursement pathway through the same HME/DME channel as their core products and highlighted their ability to scale it faster due to market access expertise, positioning it as a tuck-in acquisition with immediate accretive potential to both revenue growth and profitability post-integration.
ResMed's real-world data reveals a powerful synergy between PAP therapy and GLP-1 weight-loss drugs, showing patients who start GLP-1 after PAP have 5.1% higher two-year and 6.2% higher three-year resupply rates, while those with concurrent prescriptions are 11% more likely to initiate PAP therapy and over 6% more likely to achieve a three-year resupply event; this positions ResMed to capitalize on the once-in-a-generation demand generation from the GLP-1 megatrend, effectively converting obesity-related awareness into sleep apnea diagnosis and treatment initiation, a lever management explicitly described as a "better together" opportunity that is not yet fully priced into the stock.
The company's residential care software segment, particularly the MediFox Dan vertical, delivered 4% constant currency revenue growth despite headwinds in senior living and long-term care, indicating underlying strength in high-growth software assets; management expressed confidence in accelerating RCS revenue back to sustainable high single-digit growth with double-digit operating profit growth by fiscal 2027 through disciplined portfolio management, suggesting this segment is poised for a reacceleration that could contribute meaningfully to overall margin expansion as software typically carries higher incremental margins than hardware.
ResMed's long-term gross margin accretion plan through 2030, targeting double-digit basis points improvements annually, is supported by a deep pipeline of supply chain optimization initiatives including platform standardization, vendor management, longer-term contracts, manufacturing execution enhancements (cycle times, asset utilization), and freight optimization; this structural approach to offsetting component cost inflation demonstrates resilience beyond temporary efficiencies, reinforcing the sustainability of their 62.8% gross margin and providing a clear path to continued operating leverage as revenue scales.

ResMed's core mask portfolio, particularly the AirTouch N30i fabric-based technology, demonstrates a compelling competitive advantage with 6% higher 90-day adherence compared to silicone equivalents, which directly translates to increased patient lifetime value and resupply rates; this innovation is gaining strong early adoption in the higher-margin full-face category with the F30i Comfort and F30i Clear, and management noted these masks are "changing the basis of competition," creating a structural moat that is underappreciated by the market as a key driver of sustainable margin expansion beyond transient cost improvements.
The strategic acquisition of Noctrix Health for $340 million presents a significant hidden catalyst, as it brings a FDA de novo classified noninvasive nerve stimulation device (NIDRA) for restless leg syndrome (RLS), a condition affecting approximately 7% of the global adult population and 17 million in the U.S., with higher growth rates and gross margins than ResMed's existing business; management emphasized Noctrix's reimbursement pathway through the same HME/DME channel as their core products and highlighted their ability to scale it faster due to market access expertise, positioning it as a tuck-in acquisition with immediate accretive potential to both revenue growth and profitability post-integration.
ResMed's real-world data reveals a powerful synergy between PAP therapy and GLP-1 weight-loss drugs, showing patients who start GLP-1 after PAP have 5.1% higher two-year and 6.2% higher three-year resupply rates, while those with concurrent prescriptions are 11% more likely to initiate PAP therapy and over 6% more likely to achieve a three-year resupply event; this positions ResMed to capitalize on the once-in-a-generation demand generation from the GLP-1 megatrend, effectively converting obesity-related awareness into sleep apnea diagnosis and treatment initiation, a lever management explicitly described as a "better together" opportunity that is not yet fully priced into the stock.
The company's residential care software segment, particularly the MediFox Dan vertical, delivered 4% constant currency revenue growth despite headwinds in senior living and long-term care, indicating underlying strength in high-growth software assets; management expressed confidence in accelerating RCS revenue back to sustainable high single-digit growth with double-digit operating profit growth by fiscal 2027 through disciplined portfolio management, suggesting this segment is poised for a reacceleration that could contribute meaningfully to overall margin expansion as software typically carries higher incremental margins than hardware.
ResMed's long-term gross margin accretion plan through 2030, targeting double-digit basis points improvements annually, is supported by a deep pipeline of supply chain optimization initiatives including platform standardization, vendor management, longer-term contracts, manufacturing execution enhancements (cycle times, asset utilization), and freight optimization; this structural approach to offsetting component cost inflation demonstrates resilience beyond temporary efficiencies, reinforcing the sustainability of their 62.8% gross margin and providing a clear path to continued operating leverage as revenue scales.

▼ Bear case

ResMed's SG&A expenses increased 14% headline and 9% constant currency, rising to 19.5% of revenue, driven by VertuOx integration, employee costs, and technology investments; while management frames this as strategic, the persistent elevation in SG&A as a percentage of revenue raises concerns about operating leverage sustainability, especially as the company invests heavily in Noctrix Health and GLP-1 related demand generation without clear near-term margin contribution, potentially pressuring earnings growth despite revenue expansion.
The residential care software business faces ongoing pressure in the senior living and long-term care vertical, which offset growth from the high-performing MediFox Dan segment, resulting in only 4% constant currency revenue growth; management's confidence in returning to high single-digit growth by fiscal 2027 remains unproven, and the segment's mixed performance suggests structural challenges in certain healthcare IT markets that could limit the scalability and profitability of this diversification effort beyond what is currently anticipated.
Despite strong real-world data showing improved adherence with combined PAP and GLP-1 therapy, ResMed downplayed the impact of GLP-1 drugs on demand in the Reuters news coverage, creating a potential disconnect between internal optimism and external messaging; if the perceived threat of GLP-1s reducing sleep apnea prevalence through weight loss gains traction among investors or payers, it could undermine the long-term addressable market for PAP devices, particularly as oral GLP-1 formulations expand access and may lead to earlier intervention that alters disease progression dynamics in ways not yet fully understood by the company's current data sets.
The Noctrix Health acquisition, while strategically sound, carries integration and execution risks: the company is in an early development cycle requiring continued R&D and SG&A investment, and management acknowledged the EPS dilution impact of approximately $0.02 for Q4 fiscal 2026 with limited clarity on future accretion timing; if reimbursement for NIDRA faces delays or changes—despite current HME/DME channel alignment—or if adoption by sleep physicians lags due to entrenched pharmaceutical prescribing habits, the expected growth and margin acceleration may not materialize as planned, turning the tuck-in into a drag on resources.
Competitive dynamics in the devices segment, while currently dismissed as "no new competitive threat," could evolve rapidly given the company's acknowledgment of AI adoption challenges and the mention of emerging technologies like SmartCare; as ResMed focuses on incremental improvements in comfort, connectivity, and intelligence, a well-funded competitor could leverage disruptive innovations in sensor technology, alternative therapies, or direct-to-consumer models that circumvent traditional HME channels, particularly in key growth markets like Latin America and China where localized ecosystem strategies may not fully insulate them from agile new entrants.

ResMed's SG&A expenses increased 14% headline and 9% constant currency, rising to 19.5% of revenue, driven by VertuOx integration, employee costs, and technology investments; while management frames this as strategic, the persistent elevation in SG&A as a percentage of revenue raises concerns about operating leverage sustainability, especially as the company invests heavily in Noctrix Health and GLP-1 related demand generation without clear near-term margin contribution, potentially pressuring earnings growth despite revenue expansion.
The residential care software business faces ongoing pressure in the senior living and long-term care vertical, which offset growth from the high-performing MediFox Dan segment, resulting in only 4% constant currency revenue growth; management's confidence in returning to high single-digit growth by fiscal 2027 remains unproven, and the segment's mixed performance suggests structural challenges in certain healthcare IT markets that could limit the scalability and profitability of this diversification effort beyond what is currently anticipated.
Despite strong real-world data showing improved adherence with combined PAP and GLP-1 therapy, ResMed downplayed the impact of GLP-1 drugs on demand in the Reuters news coverage, creating a potential disconnect between internal optimism and external messaging; if the perceived threat of GLP-1s reducing sleep apnea prevalence through weight loss gains traction among investors or payers, it could undermine the long-term addressable market for PAP devices, particularly as oral GLP-1 formulations expand access and may lead to earlier intervention that alters disease progression dynamics in ways not yet fully understood by the company's current data sets.
The Noctrix Health acquisition, while strategically sound, carries integration and execution risks: the company is in an early development cycle requiring continued R&D and SG&A investment, and management acknowledged the EPS dilution impact of approximately $0.02 for Q4 fiscal 2026 with limited clarity on future accretion timing; if reimbursement for NIDRA faces delays or changes—despite current HME/DME channel alignment—or if adoption by sleep physicians lags due to entrenched pharmaceutical prescribing habits, the expected growth and margin acceleration may not materialize as planned, turning the tuck-in into a drag on resources.
Competitive dynamics in the devices segment, while currently dismissed as "no new competitive threat," could evolve rapidly given the company's acknowledgment of AI adoption challenges and the mention of emerging technologies like SmartCare; as ResMed focuses on incremental improvements in comfort, connectivity, and intelligence, a well-funded competitor could leverage disruptive innovations in sensor technology, alternative therapies, or direct-to-consumer models that circumvent traditional HME channels, particularly in key growth markets like Latin America and China where localized ecosystem strategies may not fully insulate them from agile new entrants.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password